Zhihua Zheng

Dr. Zhihua Zheng


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 October 2022 in Science Translational Medicine
Verified
Journal Article
Closed access
Achi HaiderAchi Haider
Achi Haider
CZChunyu Zhao
Chunyu Zhao
LWLu Wang
Lu Wang
ZXZhiwei Xiao
Zhiwei Xiao
JRJian Rong
Jian Rong
SLSteven H. Liang
Steven H. Liang
Alterations in brain cholesterol homeostasis have been broadly implicated in neurological disorders. Notwithstanding the complexity by which cholesterol biology is governed in the mammalian brain, excess neuronal cholesterol is primarily eliminated by metabolic clearance via cytochrome P450 46A1 (CYP46A1). No methods are currently available for visualizing cholesterol metabolism in the living human brain; therefore, a noninvasive technology that quantitatively measures the extent of brain cholesterol metabolism via CYP46A1 could broadly affect disease diagnosis and treatment options using targeted therapies. Here, we describe the development and testing of a CYP46A1-targeted positron emission tomography (PET) tracer, 18 F-CHL-2205 ( 18 F-Cholestify). Our data show that PET imaging readouts correlate with CYP46A1 protein expression and with the extent to which cholesterol is metabolized in the brain, as assessed by cross-species postmortem analyses of specimens from rodents, nonhuman primates, and humans. Proof of concept of in vivo efficacy is provided in the well-established 3xTg-AD murine model of Alzheimer’s disease (AD), where we show that the probe is sensitive to differences in brain cholesterol metabolism between 3xTg-AD mice and control animals. Furthermore, our clinical observations point toward a considerably higher baseline brain cholesterol clearance via CYP46A1 in women, as compared to age-matched men. These findings illustrate the vast potential of assessing brain cholesterol metabolism using PET and establish PET as a sensitive tool for noninvasive assessment of brain cholesterol homeostasis in the clinic.

12 January 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
JXJingwen Xie
Jingwen Xie
XHXiaoyan Huang
Xiaoyan Huang
MGMin Gao
Min Gao
LWLi Wei
Li Wei
RWRuolun Wang
Ruolun Wang
XLXiaoyan Li
Xiaoyan Li
Drug-related problems (DRPs) are common among surgical patients, especially older patients with polypharmacy and underlying diseases. DRPs can potentially lead to morbidity, mortality, and increased treatment costs. The enhanced recovery after surgery (ERAS) system has shown great advantages in managing surgical patients. Medication therapy management for surgical patients (established as “surgical pharmacy” by Guangdong Province Pharmaceutical Association (GDPA)) is an important part of the ERAS system. Improper medication therapy management can lead to serious consequences and even death. In order to reduce DRPs further, and promote the rapid recovery of surgical patients, the need for pharmacists in the ERAS program is even more pressing. However, the medication therapy management services of surgical pharmacy and how surgical pharmacists should participate in ERAS programs are still unclear worldwide. Therefore, this article reviews the main perioperative medical management strategies and precautions from several aspects, including antimicrobial agents, antithrombotic agents, pain medication, nutritional therapy, blood glucose monitoring, blood pressure treatment, fluid management, treatment of nausea and vomiting, and management of postoperative delirium. Additionally, the way surgical pharmacists participate in perioperative medication management, and the relevant medication pathways are explored for optimizing medication therapy management services within the ERAS programs. This study will greatly assist surgical pharmacists’ work, contributing to surgeons accepting that pharmacists have an important role in the multidisciplinary team, benefitting medical workers in treating, counseling, and advocating for their patients, and further improving the effectiveness, safety and economy of medication therapy for patients and promoting patient recovery.

21 June 2017 in Indian Pediatrics
Verified
Journal Article
Closed access
PDF file
ZZZhihua Zheng
Zhihua Zheng
MYMin Yang
Min Yang
JWJunyan Wu
Junyan Wu

27 February 2020 in European Journal of Hospital Pharmacy
Verified
Journal Article
Closed access
PDF file
ZZZhihua Zheng
Zhihua Zheng
JWJunyan Wu
Junyan Wu
YZYingtong Zeng
Yingtong Zeng
RWRuolun Wang
Ruolun Wang
JWJinghao Wang
Jinghao Wang
YWYong Wang
Yong Wang

16 May 2017 in European Journal of Hospital Pharmacy
Verified
Journal Article
Closed access
PDF file
ZZZhihua Zheng
Zhihua Zheng
YZYingtong Zeng
Yingtong Zeng
HHHongbing Huang
Hongbing Huang
Off-label drug use is a global issue, which is not uniformly regulated across the world. There is no legislation on off-label drug use in China, while some public media reports in the country said that off-label drug use was illegal and of concern to Chinese healthcare professionals. The Guangdong Province Pharmaceutical Association issued consensuses on off-label drug use in 2010 and 2014, which are the first sets of standards for off-label drug use in China, and has done a lot of work to change the perspective on off-label drug use …

10 June 2021 in European Journal of Hospital Pharmacy
Verified
Journal Article
Closed access
PDF file
ZZZhihua Zheng
Zhihua Zheng
JWJunyan Wu
Junyan Wu
LWLi Wei
Li Wei
XLXiaoyan Li
Xiaoyan Li
BJBo Ji
Bo Ji
HWHongwei Wu
Hongwei Wu